Overview
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Early trials show it may produce even greater weight loss than tirzepatide, potentially up to 24% body weight reduction.
How It Works
Retatrutide uniquely activates three receptors: GLP-1 for appetite suppression, GIP for enhanced insulin response, and glucagon receptor for increased energy expenditure and fat burning. This triple action addresses multiple metabolic pathways.
Research Status
Phase 3 clinical trials ongoing. Phase 2 showed 24.2% weight loss at highest dose. Expected FDA submission 2025-2026.
Purchase Retatrutide
Get high-quality, research-grade Retatrutide from our trusted partner.
Shop at ChampionPeptidesRelated Peptides
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that provides even greater weight loss than semaglutide alone. It's the newest generation of incretin-based therapies, showing unprecedented results in clinical trials.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, which is released after eating. It's one of the most effective peptides for weight loss and blood sugar control, FDA-approved for diabetes and obesity treatment.
AOD-9604
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal portion of human growth hormone (amino acids 176-191). It was developed to harness growth hormone's lipolytic (fat-burning) properties without affecting blood sugar or growth.
Related Peptides
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that provides even greater weight loss than semaglutide alone. It's the newest generation of incretin-based therapies, showing unprecedented results in clinical trials.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, which is released after eating. It's one of the most effective peptides for weight loss and blood sugar control, FDA-approved for diabetes and obesity treatment.
AOD-9604
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal portion of human growth hormone (amino acids 176-191). It was developed to harness growth hormone's lipolytic (fat-burning) properties without affecting blood sugar or growth.